Unavailable
Unavailable
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
4/22/2024 | Outperform | Exane BNP Paribas | |
11/1/2023 | $39.00 → $29.00 | Buy → Hold | Jefferies |
9/26/2023 | $33.00 | Overweight | Stephens |
9/19/2023 | Market Outperform | CJS Securities | |
8/24/2023 | $34.00 | Overweight → Equal-Weight | Morgan Stanley |
3/9/2022 | $30.00 → $22.00 | Overweight | Morgan Stanley |
3/9/2022 | $30.00 → $24.00 | Buy | B of A Securities |
3/9/2022 | $26.00 → $21.00 | Overweight | Wells Fargo |
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue for the third quarter of 2024 increased 2% to €277.9 million, compared with the same period last year, and high-value solutions represented 36% of total revenue. For the third quarter, diluted earnings per share were €0.11 and adjusted diluted earnings per share were €0.12. Adjusted EBITDA margin for the third quarter was 22.9%. The Company is maintaining its fiscal year 2024 revenue guida
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 5, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-regi
The platform provides a versatile pre-filled and pre-loaded on-body solution, suitable for highly viscous biological drugs Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, announced today the expansion of its Vertiva® platform, which will include a 10mL option to be presented at CPHI Milan in October. The Vertiva® easy-to-use platform can be pre-programmed to accommodate different motor driven dosing profiles, from micro-precision basal delivery to full-content bolus injections. This flexibility makes the platform ideal for administering a wide range of small molecule
SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)
SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)
SC 13G - Stevanato Group S.p.A. (0001849853) (Subject)
6-K - Stevanato Group S.p.A. (0001849853) (Filer)
6-K - Stevanato Group S.p.A. (0001849853) (Filer)
6-K - Stevanato Group S.p.A. (0001849853) (Filer)
Exane BNP Paribas initiated coverage of Stevanato Group S.p.A. with a rating of Outperform
Jefferies downgraded Stevanato Group S.p.A. from Buy to Hold and set a new price target of $29.00 from $39.00 previously
Stephens initiated coverage of Stevanato Group S.p.A. with a rating of Overweight and set a new price target of $33.00
-All Resolutions Proposed to Shareholders Passed- Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders ("AGM") held virtually on May 22, 2024, have passed. Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.stevanatogroup.com/. Shareholders approved, among other things, th
Strengthening corporate leadership aims to drive operational efficiencies and standardization of global processes. Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404727049/en/Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire) The addition of Ugo Gay underscores Stevanato Group's unwavering commitment to driving opera
The appointment bolsters company's commitment to growth in the region Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220202005514/en/Riccardo Butta (Photo: Business Wire) The appointment of a dedicated executive to lead the Company's long-term strategy in the Americas is indicative of the growing regional demand trends and the Company's commitment to broaden its footprint, accelerate i
Morgan Stanley analyst Drew Ranieri maintains Stevanato Gr (NYSE:STVN) with a Equal-Weight and lowers the price target from $26 to $22.
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life science industries, today announced the inauguration of its Cisterna di Latina plant. Located just a few kilometers from the Group's first historic plant in Latina, the new site covers an area of 65,000 square meters and employs around 200 people. The facility started commercial production in Q4 2023 and houses advanced production lines developed by Stevanato Group for the production of EZ-fill® pre-sterilized syringes with the aim of responding to the modern challenges of the European market, constantly growing in biopharma
Stevanato is succeeding as Chief Executive Officer Franco Moro, whose employment agreement will continue through June 30, 2024. Moro will remain on the Company's Board of Directors.
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue for the third quarter of 2024 increased 2% to €277.9 million, compared with the same period last year, and high-value solutions represented 36% of total revenue. For the third quarter, diluted earnings per share were €0.11 and adjusted diluted earnings per share were €0.12. Adjusted EBITDA margin for the third quarter was 22.9%. The Company is maintaining its fiscal year 2024 revenue guida
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 5, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-regi
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue for the second quarter of 2024 increased 2% to €259.6 million, compared with the same period last year, and high-value solutions represented 40% of total revenue. For the second quarter, diluted earnings per share were €0.08 and adjusted diluted earnings per share were €0.09. Adjusted EBITDA margin for the second quarter was 20.8%. The Company is updating its fiscal year 2024 guidan